Drug Trial Radar · NCT05632939
ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer.
Last checked: Nov 19, 2026Latest source record: Sep 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
62
Actual
Start
Feb 21, 2023
Primary completion
Oct 31, 2025
Study completion Feb 10, 2026
Sponsor
- Lead sponsor
- AskGene Pharma, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Jiangsu Aosaikang Pharmaceutical Co., Ltd.
- First posted
- Dec 1, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was an open-label, phase 1/2 study to evaluate safety, tolerability, pharmacokinetics, and antitumor activity of ASKB589 in combination with CAPOX and PD-1 inhibitors in first-line treatment of patients with locally advanced, recurrent, or metastatic gastric and esophagogastric junction adenocarcinoma.
Conditions
- Gastric Cancer
- Gastroesophageal Cancer (GC)
Interventions
ASKB589 +CAPOX+Sintilimab/TislelizumabDrug
Oxaliplatin: intravenous infusion, 130mg/m2, infusion for more than 3h, every 3 weeks for a cycle, infusion 6 cycles; Capecitabine: oral administration, 1000mg/m2, 2 times, 14 days, 7 days rest, every 3 weeks for a cycle; Sintilimab/Tislelizumab was administered intravenously at 200mg. The drug was administered once every 3 weeks, and the longest cumulative duration was 2 years. ASKB589 is administered intravenously at a fixed dose. The drug was given once every 3 weeks for a cycle, with the longest cumulative duration of 2 years.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events as assessed by CTCAE v5.0Time frame: up to 21 days following last dose
- The incidence and case number of DLT (Dose Limiting Toxicity) during observation period.Time frame: up to 21 days following last dose
- Maximum Tolerated Dose (MTD)Time frame: up to 21 days following last dose
- The recommended doseTime frame: from date of treatment start until data cut-off, up to 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.